United Therapeutics Co. (UTHR) Receives $133.63 Average Target Price from Analysts

United Therapeutics Co. (NASDAQ:UTHR) has been given an average rating of “Hold” by the thirteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $133.63.

Several equities analysts have recently issued reports on UTHR shares. BidaskClub downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 31st. TheStreet raised shares of United Therapeutics from a “c+” rating to a “b-” rating in a report on Monday, February 11th. Cowen reissued a “hold” rating and set a $109.00 price target on shares of United Therapeutics in a report on Wednesday, February 27th. LADENBURG THALM/SH SH set a $124.00 price target on shares of United Therapeutics and gave the company a “hold” rating in a report on Thursday, February 28th. Finally, Barclays reduced their price target on shares of United Therapeutics from $100.00 to $95.00 and set an “underweight” rating for the company in a report on Friday, March 1st.

In other United Therapeutics news, Director Christopher Patusky sold 3,370 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $110.75, for a total value of $373,227.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 8.20% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its position in United Therapeutics by 1.1% in the first quarter. BlackRock Inc. now owns 4,994,759 shares of the biotechnology company’s stock worth $586,236,000 after acquiring an additional 52,760 shares in the last quarter. Vanguard Group Inc raised its position in United Therapeutics by 1.7% in the third quarter. Vanguard Group Inc now owns 3,775,103 shares of the biotechnology company’s stock worth $482,760,000 after acquiring an additional 61,361 shares in the last quarter. Oregon Public Employees Retirement Fund raised its position in United Therapeutics by 10,537.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,551,229 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 3,517,845 shares in the last quarter. First Trust Advisors LP raised its position in United Therapeutics by 7.8% in the first quarter. First Trust Advisors LP now owns 1,290,590 shares of the biotechnology company’s stock worth $151,477,000 after acquiring an additional 93,786 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in United Therapeutics by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,088,982 shares of the biotechnology company’s stock worth $118,583,000 after acquiring an additional 29,427 shares in the last quarter. Hedge funds and other institutional investors own 97.65% of the company’s stock.

UTHR stock opened at $94.64 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.19 and a quick ratio of 6.84. United Therapeutics has a 1-year low of $93.27 and a 1-year high of $130.00. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of 7.07 and a beta of 1.01.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share for the quarter, missing the consensus estimate of $2.64 by ($13.96). United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The business had revenue of $362.70 million for the quarter, compared to the consensus estimate of $335.72 million. During the same quarter in the previous year, the firm earned $3.76 EPS. The firm’s revenue for the quarter was down 6.8% on a year-over-year basis. Equities research analysts predict that United Therapeutics will post -5.03 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

See Also: Economic Reports

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.